Up until now, current treatments for actinic keratosis (AK) have been far from perfect, but because AK is thought to be a precursor to squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), an imperfect treatment was better than none. Often referred to as sunspots, or solar keratosis, the potential for these to morph into a melanoma is real and early treatment is the best option. A new simple treatment, without side effects, is now available and I would like to discuss it with you today
Actinic keratoses are scaly, red and occasionally itchy patches on areas of exposed skin — usually on patients over 50 years old, but can manifest in younger adults, particularly with prolonged sun exposure. Current treatments include photodynamic therapy, or a selection of topical products that present side effects worse than the original lesion. All of these require several weeks of application for treatment to work and they tend to cause a huge inflammatory skin response — meaning compliance becomes an issue and patients do not continue through with the treatments.
But recently I came across a new topical cream that not only shows promise in treatment of AK, but may also have the ability to regress early stage Basal Cell Carcinoma, without any visible side effects.
The product, marketed under the brand name of ZenaDerm, is a cream utilising the active ingredients found in Tea Tree Oil, known as terpinen-4-ol. In clinical trials on Tea Tree Oil, first conducted at the University of Western Australia by a team of doctors headed up by Professor Thomas V Riley, and then later with 5 clinical trials on ZenaDerm at the University of Kentucky conducted by Professor Don Cohen, this product showed remarkable ability to regress early stage Basal Cell Carcinoma.
Although the exact mode of action is unknown for Tea Tree Oil, one study showed that TTO appeared to stimulate an immune response (i.e. neutrophils, dendritic, and T Cells) and anti-tumor efficacy is facilitated by a direct effect on subcutaneous AE17 tumor cells in vivo Ireland et al. (2012)
Whatever the mode of action, several clinical trials support the efficacy of Tea Tree Oil and its active components, and importantly the product appears to work effectively without any visible side effects. In my opinion that is probably the products most valuable attribute, because if it is easy to use and there aren’t any side effects, patients are more likely to continue using it for the full course (in this case 7-10 days) and results will be better.
In my opinion this product shows great promise for the treatment of Actinic Keratosis, and it's less dangerous cousin, Seborrheic Keratosis, and should be considered an option in the treatment of these dangerous and unsightly lesions. ZenaDerm is manufactured in Australia and sold worldwide through Global Health Direct.
Readers of Newmaker.com.au can get a wonderful bonus, in the form of a second bottle for free, and I greatly appreciate the company’s generosity in these trying times to help our readers. I believe that shipping is also free, no matter what country you live in. If you try it out I would love to hear your feedback on the results, and so far my patients who have tried it are giving the product glowing reviews. You can always email me questions or comments at [email protected]
Author: Dr David Goldstein for naturalhealthmedia.com
Natural Health Media
Natural Health Media, a division of the Complimentary Healthcare Group (CHG), provides media articles backed by clinical data and research on complimentary options for healthcare. Supported by a unique group of Doctors from around the world, NHM provides a snapshot on alternative health and the growing clinical evidence to support the uses of alternative medicines.
Dr David Goldstein
Complimentary Healthcare Group
CHG provides media articles backed by clinical data and research on complimentary options for healthcare. Supported by a unique group of Doctors around the world, CHG provides a snapshot on alternative health and the growing clinical evidence to support the uses of alternative medicines.
Dr. Richard Teague